AdvaMed responds to CMS 2026 payment rule, stressing patient access to diabetes and prosthetic supplies amid competitive bidding concerns.

Pharmaceutical companies agree to significant Medicare drug price cuts under Trump administration, projecting billions in savings with impacts on Medicare Part D and drug affordability.

CMS proposes to revamp Medicare Advantage Star Ratings, affecting insurer compliance and operations. Legal appeals and health system updates also impact the US market.

The expiration of enhanced ACA health insurance subsidies could double premiums, reduce coverage for millions, and strain state budgets, with significant economic and healthcare impacts nationwide.

President Trump's plan to extend expiring Obamacare subsidies encounters GOP opposition and sparks bipartisan talks to prevent premium hikes and reform healthcare funding.

Medicare 2026 premiums surge nearly 10%, with fewer Medicare Advantage plans as insurers scale back. Explore key Medicare cost drivers and market impacts.

The U.S. government passed H.R. 5371, ending the shutdown and extending Medicare telehealth flexibilities through January 2026, ensuring continued coverage and retroactive payments for telehealth claims.

CMS introduces the Ambulatory Specialty Model, a new mandatory payment model for specialists treating low back pain and heart failure, effective from 2027 to improve care quality and reduce costs.

Examining Aetna's new inpatient payment policy for Medicare Advantage plans, its conflicts with Medicare's Two-Midnight Rule, and implications for hospital reimbursement and compliance.

Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.